AVR(AVR)
AVR
11/19/26
Anteris Technologies Global (AVR)
Thursday
3:47 PM ET
ThesisAnteris Technologies Global: the story is balanced — Clinical trial enrollment milestones and interim data readouts from US IDE pivotal trial and European studies
Revenue Outlook
What Moves the Stock
- 01Clinical trial enrollment milestones and interim data readouts from US IDE pivotal trial and European studies
- 02Regulatory progress - FDA breakthrough device designation updates, IDE approval stages, CE Mark submission timing
- 03Capital raises and cash runway visibility given -$8M quarterly burn rate and 0.84x current ratio
- 04Partnership or licensing announcements for ADAPT technology or commercial distribution rights
- 05Competitive TAVR durability data from Edwards/Medtronic that validates or challenges Anteris's differentiation thesis
- 06DurAVR TAVR system sales (future - currently pre-commercial)
- 07Potential licensing of ADAPT tissue technology to other device manufacturers
- 08Surgical valve products using ADAPT technology (future expansion)
FY2025 Snapshot
- Revenue
- $2M
- Rev. Growth
- -29.2%
- Gross Margin
- -16.6%
- Op. Margin
- -4908%
- Net Margin
- -4921%
- Net Income
- $-94M
- NI Growth
- -23.4%
- EPS
- $-2.55
- 1Y Return
- +44.9%
AVR Chart
My Notes
- growth/speculative - Attracts high-risk biotech investors seeking asymmetric returns from successful clinical development and regulatory…
- Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (estimated commercialization…
- Watch on earnings: Monthly cash burn rate and quarters of runway to next financing event, Clinical trial patient enrollment velocity versus targeted timelines, FDA correspondence and regulatory pathway clarity for pivotal trial design.
One Sentence Summary:
Anteris Technologies Global: the story is balanced — clinical trial enrollment milestones and interim data readouts from us ide pivotal trial and european studies.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
AVR Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance